Intravitreal angiostatisk behandling af okulær sygdom

Translated title of the contribution: Intravitreal angiostatic treatment of ocular vascular diseases

Lou-Ann Christensen Andersen, Lasse Jørgensen Cehofski, Jakob Grauslund

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Intraocular vascular diseases like neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion are associated with decline in vision if left untreated. Anti-vascular endothelia growth factor (VEGF) agents originally developed for cancer treatment were the beginning of a new treatment regime for intraocular vascular diseases. Ambiguous results exist regarding adverse effects but are considered limited. In the future, anti-VEGF agents are likely to be used for treatment of proliferative diabetic retinopathy, neovascular glaucoma and premature retinopathy.
Translated title of the contributionIntravitreal angiostatic treatment of ocular vascular diseases
Original languageDanish
Article numberV04190256
JournalUgeskrift for Laeger
Volume182
Issue number10
Number of pages4
ISSN0041-5782
Publication statusPublished - 2020

Fingerprint Dive into the research topics of 'Intravitreal angiostatic treatment of ocular vascular diseases'. Together they form a unique fingerprint.

Cite this